Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A. Zill OA, et al. Among authors: fairclough sr. Clin Cancer Res. 2018 Aug 1;24(15):3528-3538. doi: 10.1158/1078-0432.CCR-17-3837. Epub 2018 May 18. Clin Cancer Res. 2018. PMID: 29776953
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.
Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O. Rich TA, et al. Clin Cancer Res. 2019 Oct 1;25(19):5832-5842. doi: 10.1158/1078-0432.CCR-18-4049. Epub 2019 Jul 12. Clin Cancer Res. 2019. PMID: 31300450 Free PMC article.
Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients.
Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy RJ, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR. Hu Y, et al. Among authors: fairclough sr. Clin Cancer Res. 2017 Dec 1;23(23):7351-7359. doi: 10.1158/1078-0432.CCR-17-1745. Epub 2017 Sep 25. Clin Cancer Res. 2017. PMID: 28947568 Free PMC article.
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies.
Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, Fairclough SR, Zill OA, Sikora M, Mokhtari R, Abdueva D, Nagy RJ, Lee CE, Kiedrowski LA, Paweletz CP, Eltoukhy H, Lanman RB, Chudova DI, Talasaz A. Odegaard JI, et al. Among authors: fairclough sr. Clin Cancer Res. 2018 Aug 1;24(15):3539-3549. doi: 10.1158/1078-0432.CCR-17-3831. Epub 2018 Apr 24. Clin Cancer Res. 2018. PMID: 29691297
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.
Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI. Willis J, et al. Among authors: fairclough sr. Clin Cancer Res. 2019 Dec 1;25(23):7035-7045. doi: 10.1158/1078-0432.CCR-19-1324. Epub 2019 Aug 4. Clin Cancer Res. 2019. PMID: 31383735
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors.
Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Vidula N, et al. Among authors: fairclough sr. Clin Cancer Res. 2020 Jun 1;26(11):2546-2555. doi: 10.1158/1078-0432.CCR-19-2933. Epub 2020 Feb 7. Clin Cancer Res. 2020. PMID: 32034076
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.
Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Taxter T, Kuzel TM, Fan A, Chae YK, Cristofanilli M, Hussain MH, Abdulkadir SA, Giles FJ. Carneiro BA, et al. JCO Precis Oncol. 2018;2:PO.17.00176. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14. JCO Precis Oncol. 2018. PMID: 31501807 Free PMC article.
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzulli A, Trusolino L, Siena S, Marsoni S, Bardelli A. Siravegna G, et al. Cancer Cell. 2018 Jul 9;34(1):148-162.e7. doi: 10.1016/j.ccell.2018.06.004. Cancer Cell. 2018. PMID: 29990497 Free article. Clinical Trial.
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, Cherniack AD, Price KS, Fairclough SR, Nishino M, Sholl LM, Oxnard GR, Jänne PA, Awad MM. Recondo G, et al. Among authors: fairclough sr. Clin Cancer Res. 2020 Jun 1;26(11):2615-2625. doi: 10.1158/1078-0432.CCR-19-3608. Epub 2020 Feb 7. Clin Cancer Res. 2020. PMID: 32034073
18 results